Increased mortality risk in people with schizophrenia in Lithuania 2001-2020
- PMID: 39820533
- PMCID: PMC11739394
- DOI: 10.1038/s41537-024-00549-y
Increased mortality risk in people with schizophrenia in Lithuania 2001-2020
Abstract
The aim of this study was to assess mortality risk in people with schizophrenia in Lithuania from 2001 and 2020. Cause-specific and all-cause mortality risk among patients with schizophrenia was assessed using a retrospective cohort study design. The cohort identified all patients with schizophrenia diagnosis (ICD-10 code F20) who were admitted to the Vilnius Republican Psychiatric Hospital from 1 January, 2001 to December 31, 2020. Dates of death and emigration were obtained from the Central Population Register. The standardized mortality ratios (SMRs) were calculated by dividing the observed number of deaths among patients with schizophrenia by the expected number of deaths, calculated using the national rates. The final cohort included 7883 patients, with 2458 observed deaths. An increased all-cause mortality risk was found for both sexes (SMR = 1.96; 95% CI 1.88-2.04) compared to the general population. The most common cause-specific mortality risk was found for diseases of the circulatory system (SMR = 2.17; 95% CI 2.05-2.30). Other significant increases in cause-specific mortality risk were observed for infectious diseases, mental and behavioural disorders, diseases of the nervous system and respiratory system, diseases of the genitourinary system, as well as external causes. Patients with schizophrenia do not benefit from the health strategies that have led to reduced mortality in the general population. To close the mortality gap, smoking and alcohol cessation interventions, cardiovascular and cancer screening and monitoring, early diagnosis, and interventions for identified physical diseases should be regarded as imperative.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: The authors declare no competing interests. Declaration of generative AI and AI-assisted technologies in the writing process: During the preparation of this work, the authors did not use any generative AI or AI-assisted technologies. Ethical approval: This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Vilnius regional biomedical research ethics committee (approval number No. 2022/6-1449-915 on 14 June 2022). Informed consent: Patients’ consent was waived to this study.
References
-
- Volavka, J. & Vevera, J. Very long-term outcome of schizophrenia. Int. J. Clin. Pract.72, e13094 (2018). - PubMed
-
- Saha, S., Chant, D. & McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry64, 1123–1131 (2007). - PubMed
-
- Hjorthøj, C., Stürup, A. E., McGrath, J. J. & Nordentoft, M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry4, 295–301 (2017). - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous